Embera NeuroTherapeutics, Inc., is a specialty biopharmaceutical company focused on developing treatments for smoking cessation, cocaine use disorder and other addictions, for which there are a limited range of effective drug therapies or no approved treatment options. Embera is developing a novel, patented drug combination (EMB-001) targeting specific brain functions related to stress response that drive craving and relapse associated with these disorders, an approach based on years of NIH-funded research on the role of stress in addiction and potential treatments. EMB-001 has been tested with promising clinical results in a published pilot study in cocaine-dependent human subjects.

from http://www.emberaneuro.com/

Research Grants show all

NIH1

Publications show all

Embera Neurotherapeutics has published 1 articles.

Patents show all

12Applications1Issued

Clinical Trials show all

2Phase 11N/A

SEC Filings show all

D6